{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016089","form_type":"8-K","ticker":"MGTX","cik":"0001735438","company_name":"MeiraGTx Holdings plc","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.404184+00:00","generated_at":"2026-05-29T05:43:20.445850+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MeiraGTx granted FDA RMAT designation for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia","bullets":["FDA's RMAT designation includes Fast Track, Breakthrough Therapy benefits and potential Priority Review and accelerated approval.","Phase 1 AQUAx trial showed significant patient-reported outcomes and saliva production improvements with no serious adverse events.","Phase 2 AQUAx2 double-blind, placebo-controlled trial is enrolling; FDA agreed Phase 2 may serve as pivotal trial for BLA filing.","AAV2-hAQP1 previously received FDA Orphan Drug Designation for this indication."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016089","json":"https://secwatch.observer/filing/0001558370-24-016089.json","markdown":"https://secwatch.observer/filing/0001558370-24-016089.md","text":"https://secwatch.observer/filing/0001558370-24-016089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024016089/0001558370-24-016089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1735438/000155837024016089/mgtx-20241209x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:43:20.445850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}